Xenetic is a leading UK-based biopharmaceutical company providing leading-edge expertise in the development of a whole new generation of drugs, cancer therapies and vaccines. Working with some of the largest pharmaceutical organisations in the world, Xenetic provides specialist delivery solutions to improve the efficacy and performance of drugs and vaccines in a number of key medical areas including oncology. We are also actively developing our own pipeline of next generation biotherapeutics based on our proprietary PolyXen, Oncohist and ImuXen platform technologies.
14/06/13
Analyst and Investor Conference Call06/06/13
Final Results & Notice of AGM10/05/13
Commencement of Phase II with MyeloXenT09/05/13
Commencement of dosing in Phase III study30/04/13
Entrepreneur acquires 10% of Pharmsynthez
30/04/13
Xenetic Biosciences will see US$60mln invested in two drug candidates it discovered under terms of an exciting tie-up between the AIM-listed group’s Russian partner and billionaire Dr Phil Frost.
08/02/13
Probability, ANGLE, AFC Energy and Xenetic Biosciences each has a market leading technology with the potential to transform its particular field.
19/11/12
Xenetic Biosciences has begun early stage human trials of MyeloXen, a potential vaccine for multiple sclerosis. The phase I/IIa study taking place in Russia will recruit 26 volunteers – six healthy volunteers and 20 patients – and it will be carried out three parts.
13/02/2013
Press: Xenetic Biosciences was unchanged despite gossip that Russian state technology firm Rusnano is rumoured to have acquired a strategic... read more
Press: Lipoxen rose after raising GBP14.4m in a placing, partly funded by SynBio - a new Russian company whose majority shareholder will be a... read more
Press: Lipoxen rose on news that Russian nanotechnology company SynBio has acquired shares in a placing at 11p a share and has also been... read more
Singer Capital Markets initiates coverage of Lipoxen with a 41p price target. Analyst Shawn Manning says he expects the biotech to ink... read more
the company announces a development agreement for its vaccine protecting technology with Cambridge Biostability, Cambridge University... read more
| Date | Director | Trans | Amount | Type | Price(p) | Value (£) | Holding | % |
|---|---|---|---|---|---|---|---|---|
| 23/04/10 | C.W. Hill | BUY | 150,000 | ORD | 6.83 | 10,245 | 1,825,420 | 1.06 |
| 23/04/10 | M.S. Maguire | BUY | 100,000 | ORD | 6.95 | 6,950 | 1,401,362 | 0.82 |
| 01/04/10 | Sir B.M. Richards | TAKE | 1,071,429 | ORD | 7.00 | 75,000 | 2,262,606 | 1.32 |
| 01/04/10 | M.S. Maguire | TAKE | 535,714 | ORD | 7.00 | 37,500 | 1,301,362 | 0.76 |
| 01/04/10 | C.W. Hill | TAKE | 535,714 | ORD | 7.00 | 37,500 | 1,675,420 | 0.97 |
| Date | Type | Turnover | Profit | EPS (p) | Dividend (p) | Currency |
|---|---|---|---|---|---|---|
| 31/12/12 | Full year | 0.17 | -3.38 | -0.91 | 0.00 | GBX |
| 30/06/12 | Interim | 0.01 | -1.86 | -0.47 | 0.00 | GBX |
| 31/12/11 | Full year | 0.14 | -2.85 | -1.44 | 0.00 | GBX |
| 30/06/11 | Interim | 0.06 | -1.28 | -0.72 | 0.00 | GBX |
| 31/12/10 | Full year | 1.57 | -1.93 | -1.13 | 0.00 | GBX |
Strategy
Xenetic’s strategy as a Speciality Drug Developer has at its core the Company’s three patented drug delivery platforms that allow the creation of novel and next generation drug and vaccine candidates with applications over a broad range of therapeutic areas.
While proprietary drug development in the orphan drug sector will be a first priority, the Company will continue to seek out-licensing arrangements with leading Big Bio and Big Pharma partners for the development of novel or next generation therapeutics.
Xenetic has already established a clinical record for potential blockbuster candidates for the treatment of anaemia and diabetes; and, through its various development agreements in Russia, India and elsewhere (such as that established in 2006 with Baxter Healthcare) the Company believes that the dissemination, application and commercialisation of its technologies will be better facilitated by the outlicensing of multiple product candidates currently beyond its economic capacity to develop in-house.
Science & Technology
Xenetic has developed a number of proprietary patented technologies that are being used to create a new generation of drug and vaccine products with improved performance. Xenetic’s technologies include:
PolyXen® for protein drug delivery
PolyXen® is a versatile enabling technology that uses the biopolymer polysialic acid to prolong the active life and improve the pharmacokinetics and pharmacodynamics of therapeutic peptides and proteins, as well as conventional small molecule drugs. PolyXen® is a next generation method to PEGylation for the delivery of protein drugs.
ImuXen® for vaccine delivery
ImuXen® is an advanced enabling technology that uses liposome-based constructs to boost the effectiveness of DNA, protein and polysaccharide vaccines. ImuXen® can achieve protective immunity in a single dose.
Oncohist
Oncohist™ has been established as a novel patent-protected platform technology that utilizes the special properties of human histone H1.3 as a critical component of the innate defense system for the treatment of cancer. An inducible expression system is used for large scale expression of Oncohist™ (recombinant human N-bis-met-Histone H1.3) in Escherichia coli. Oncohist™ has strong anti-proliferative properties in cancer cells of different histological origins. This has been demonstrated extensively for hematologic malignancies, such as leukaemias, lymphomas and myelomas. Oncohist™ has also the potential application across a broad spectrum of other cancers.
PolyXen
PolyXen® is an enabling technology for protein drug delivery. It uses the natural polymer polysialic acid (PSA) to prolong the active life and improve the stability of therapeutic peptides and proteins. It can also be used for small molecule drugs.
PolyXen® is an enabling technology for protein drug delivery. It uses the natural polymer polysialic acid (PSA) to prolong the active life and improve the stability of therapeutic peptides and proteins. It can also be used for small molecule drugs.
Pre-clinical proof-of-concept studies and clinical studies in man have shown that the key benefits of PolyXen® for protein drug delivery include:
For more information pease click here
ImuXen
ImuXen® is a liposomal technology platform designed to improve the delivery and effectiveness of DNA, protein and polysaccharide vaccines.
Proof of concept preclinical studies with a number of vaccines have shown that ImuXen® technology can help to generate the rapid onset of protective immune responses, in some cases following just a single dose.
The advantages of ImuXen® for DNA, protein and polysaccharide vaccines include:
For more information pease click here
Oncohist
Oncohist™ exhibits the same properties as the body's own histone H1.3 molecules and has consequently low immunogenicity and antigenicity. Extensive data have shown that Oncohist molecules have the ability to destabilize selectively the tumor cell membrane which results in cell death. The selective attack of the membrane of tumor cells is due to the ability of Oncohist™ molecules to recognize the difference in membrane structure between tumor cells and their healthy counterparts. We believe that Oncohist™ has superior advantages over conventional cancer therapeutics, including high selectivity, low inherent toxicity, lack of induction of resistance and low immunogenicity.
A pilot clinical study (phase I/II) with Acute Myeloid Leukemia (AML) patients has been performed at the Saarland University Hospital at Homburg/Saar, Germany. The data showed that Oncohist™ is safe and well tolerated by patients while the first encouraging signs of clinical effect included three partial remissions, increase of thrombocytes and normalization of leukocytes as well as stabilization for several months in two patients.
Oncohist™ has been granted orphan drug status for Acute Myeloid Leukemia (AML) by both the FDA and EMA and additional orphan drug status for Acute Lymphocytic Leukemia (ALL) in Europe by the EMA.
Number of Securities in Issue
407,875,428 Ordinary Shares of 0.5p.
All shares rank pari passu in every respect.
** Relates to JSOP shares issued on 10th June 2010 and 1st March 2012
The percentage of the Company's shares that is not in public hands is 68.13%
There are no restrictions on the transfer of the Company's shares.
This information was last updated on 20th March 2013.
Figures taken from Company website 17.06.2013
Management Office
Xenetic Biosciences plc
Greener House
66-68 Haymarket
London. SW1Y 4RF
United Kingdom
Tel : +44(0) 20 3021 1500
Fax: +44(0) 20 3021 1511
Nominated Advisors
Singer Capital Markets Limited
One Hanover Street
London
W1S 1YZ
Company Brokers
Singer Capital Markets Limited
One Hanover Street
London
W1S 1YZ
PR Advisors
Walbrook PR Limited
4 Lombard Street
London
EC3V 9HD
Reporting Accountants to Xenetic
F.W. Smith, Riches & Co
15 Whitehall
London
SW1A 2DD
Legal Advisers
Pinsent Masons LLP
30 Crown Place
London
EC2A 4ES
Auditors
Ernst & Young
Apex Plaza
Forbury Road
Reading
RG1 1YE
Registrars
Share Registrars Limited
Craven House
West Street
Farnham
Surrey
GU9 7EN
Patent Attorney
One3 IP Management
1560-1 Newbury Road
#327
Newbury Park
CA 91320
Copyright © Proactiveinvestors.co.uk, 2013. All Rights Reserved Design & Development: Tehnicom Computers
